ReviewCell research2013
A blueprint for engineering cell fate: current technologies to reprogram cell identity.
Review in Cell research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed.
- Computational Network Analysis for Defining Transcriptional Programs.Methods in molecular biology (Clifton, N.J.) · 2027Article
- PBAE nanoparticle-mediated delivery of ASCL1 and NGN2 genes for astroglia-to-neuron reprogramming to remodel glial scar for spinal cord injury repair.Stem cell research & therapy · 2026Article
- Computational blueprints for cell fate programming.Stem cell reports · 2026Review
- Designed Minibinders Rewire Receptor Signaling to Enable Functional Human Myogenic Reprogramming.bioRxiv : the preprint server for biology · 2026Article
- Mettl3 promotes reprogramming and axonogenesis of induced retinal ganglion cells.Stem cell reports · 2026Article
- Redefining cellular reprogramming with advanced genomic technologies.Nature reviews. Genetics · 2026Review
- Refate identifies chemical compounds to target trans-regulatory networks for cellular conversion.bioRxiv : the preprint server for biology · 2025Article
- Cell identity and 5-hydroxymethylcytosine.Epigenetics & chromatin · 2025Review
- TFcomb identifies transcription factor combinations for cellular reprogramming based on single-cell multiomics data.Genome research · 2025Article
- TRIAGE: an R package for regulatory gene analysis.Briefings in bioinformatics · 2025Article
- Molecular logic for cellular specializations that initiate the auditory parallel processing pathways.Nature communications · 2025Article
- Molecular logic for cellular specializations that initiate the auditory parallel processing pathways.bioRxiv : the preprint server for biology · 2024Article
- An activity-specificity trade-off encoded in human transcription factors.Nature cell biology · 2024Article
- Article
- Retinal Ganglion Cell Fate Induction by Ngn-Family Transcription Factors.Investigative ophthalmology & visual science · 2023Article
- Engineering Materials and Devices for the Prevention, Diagnosis, and Treatment of COVID-19 and Infectious Diseases.Nanomaterials (Basel, Switzerland) · 2023Review
- Reduction of Intracellular Tension and Cell Adhesion Promotes Open Chromatin Structure and Enhances Cell Reprogramming.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.Nature communications · 2023Article
- A single cell-based computational platform to identify chemical compounds targeting desired sets of transcription factors for cellular conversion.Stem cell reports · 2023Article
- Gene regulatory network reconfiguration in direct lineage reprogramming.Stem cell reports · 2023Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Human diseases such as heart failure, diabetes, neurodegenerative disorders, and many others result from the deficiency or dysfunction of critical cell types. Strategies for therapeutic tissue repair or regeneration require the in vitro manufacture of clinically relevant quantities of defined cell types. In addition to transplantation therapy, the generation of otherwise inaccessible cells also permits disease modeling, toxicology testing and drug discovery in vitro. In this review, we discuss current strategies to manipulate the identity of abundant and accessible cells by differentiation from an induced pluripotent state or direct conversion between differentiated states. We contrast these approaches with recent advances employing partial reprogramming to facilitate lineage switching, and discuss the mechanisms underlying the engineering of cell fate. Finally, we address the current limitations of the field and how the resulting cell types can be assessed to ensure the production of medically relevant populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.